Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Details)

v3.20.4
Earnings (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Basic and diluted numerator:        
Net loss attributable to iBio, Inc. stockholders $ (8,129) $ (3,762) $ (15,662) $ (8,225)
Preferred stock dividends - iBio CMO Preferred Tracking Stock (65) (65) (131) (131)
Deemed dividends - down round of Series A Preferred and Series B Preferred   (21,560) 0 (21,560)
Net loss available to iBio, Inc. stockholders $ (8,194) $ (25,387) $ (15,793) $ (29,916)
Basic and diluted denominator:        
Weighted-average common shares outstanding 188,087 36,917 175,264 29,420
Per share amount $ (0.04) $ (0.69) $ (0.09) $ (1.02)